Literature DB >> 6760767

Possible antidepressive effects of opioids: action of buprenorphine.

H M Emrich, P Vogt, A Herz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6760767     DOI： 10.1111/j.1749-6632.1982.tb39483.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  34 in total

1.  Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression.

Authors:  Marta Peciña; Amy S B Bohnert; Magdalena Sikora; Erich T Avery; Scott A Langenecker; Brian J Mickey; Jon-Kar Zubieta
Journal:  JAMA Psychiatry       Date:  2015-11       Impact factor: 21.596

Review 2.  Review: Sex-Based Differences in Treatment Outcomes for Persons With Opioid Use Disorder.

Authors:  Andrew S Huhn; Meredith S Berry; Kelly E Dunn
Journal:  Am J Addict       Date:  2019-05-26

3.  Effects of buprenorphine on responses to social stimuli in healthy adults.

Authors:  Anya K Bershad; Jacob A Seiden; Harriet de Wit
Journal:  Psychoneuroendocrinology       Date:  2015-09-12       Impact factor: 4.905

4.  Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice.

Authors:  Abdulrahman Almatroudi; Stephen M Husbands; Christopher P Bailey; Sarah J Bailey
Journal:  J Psychopharmacol       Date:  2015-06-04       Impact factor: 4.153

Review 5.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

6.  Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder.

Authors:  Margaret L Griffin; Dorian R Dodd; Jennifer S Potter; Lindsay S Rice; William Dickinson; Steven Sparenborg; Roger D Weiss
Journal:  Am J Drug Alcohol Abuse       Date:  2013-11-12       Impact factor: 3.829

Review 7.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

8.  Buprenorphine: Therapeutic potential beyond substance abuse.

Authors:  Stephani Velasquez; Jay Rappaport
Journal:  J Leukoc Biol       Date:  2018-12       Impact factor: 4.962

9.  Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.

Authors:  Andrew C Kruegel; Madalee M Gassaway; Abhijeet Kapoor; András Váradi; Susruta Majumdar; Marta Filizola; Jonathan A Javitch; Dalibor Sames
Journal:  J Am Chem Soc       Date:  2016-05-18       Impact factor: 15.419

10.  Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Authors:  Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.